Evidence map›Paper›PMID 37122532›Full record

ArticleResearch and practice in thrombosis and haemostasis2023

Platelet-activating functional assay resolution in vaccine-induced immune thrombotic thrombocytopenia: differential alignment to PF4 ELISA platforms.

Christine S M Lee, Lisa J Clarke, Geoffrey W Kershaw, Ibrahim Tohidi-Esfahani, Timothy A Brighton, Sanjeev Chunilal, Emmanuel J Favaloro, Huyen Tran, Vivien M Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Research and practice in thrombosis and haemostasis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 1 country.

Christine S M LeeANZAC Research Institute, University of Sydney, Sydney, New South Wales, Australia.
Lisa J ClarkeDepartment of Haematology, Concord Repatriation General Hospital, and NSW Health Pathology, Sydney, New South Wales, Australia.
Geoffrey W KershawInstitute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Ibrahim Tohidi-EsfahaniANZAC Research Institute, University of Sydney, Sydney, New South Wales, Australia.
Timothy A BrightonDepartment of Haematology, New South Wales Health Pathology, Prince of Wales Hospital, Randwick, Sydney, New South Wales, Australia.
Sanjeev ChunilalDepartment of Health Sciences, Monash University, Melbourne, Victoria, Australia.
Emmanuel J FavaloroDepartment of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Sydney Centres for Thrombosis and Haemostasis, NSW Health Pathology, Westmead Hospital, Westmead, New South Wales, Australia.
Huyen TranDepartment of Health Sciences, Monash University, Melbourne, Victoria, Australia.
Vivien M ChenANZAC Research Institute, University of Sydney, Sydney, New South Wales, Australia.
The University of Sydney · AUAustralian Centre for HIV and Hepatitis Virology Research · AUAustralian Red Cross Lifeblood · AUCharles Sturt University · AUConcord Repatriation General Hospital · AUMonash University · AUPrince of Wales Hospital · AURoyal Prince Alfred Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Anti-platelet factor 4 (PF4) antibodies in vaccine-induced immune thrombotic thrombocytopenia (VITT) appear to be transient, with discrepant persistence depending on the platform used for detection. Objectives: We aimed to report a longitudinal study of antibody persistence using 2 ELISA platforms and 2 platelet-activating functional assays in a clinical cohort of patients with VITT referred for follow-up testing. Methods: In total, 32 Australian patients with VITT or pre-VITT, confirmed by expert adjudication, with samples referred for clinical follow-up were included. Clinical follow-up assays, including Stago and Hyphen ELISAs, procoagulant platelet flow cytometry, and modified PF4-serotonin-release assay, were performed according to the pattern of reactivity for that patient at diagnosis. Results: The median follow-up was 24 weeks after diagnosis. A general decline in anti-PF4 antibody levels and platelet-activating capacity over time was observed with a more rapid median time to resolution of 16 weeks by functional assay vs 24 weeks by Stago ELISA. Decline in platelet-activating antibody levels detected by functional assays mirrored Stago ELISA titer but not Hyphen. However, 87% of patients received a documented second vaccination and 74% received an mRNA booster with no reported adverse events. Conclusion: Anti-PF4 antibodies persist longer than functional platelet-activating antibodies in VITT but do not warrant avoidance of subsequent vaccinations. Persistence detection is assay-dependent. Stago ELISA may be a surrogate where functional assays are unavailable for follow-up testing of confirmed patients with VITT.

Indexed as

COVID -19 vaccineenzyme-linked immunosorbent assayplatelet activationplatelet factor 4vaccine-induced immune thrombotic thrombocytopenia

Identifiers

PMID37122532
PMCPMC10139939
OpenAlexW4360955507

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.